The Therapeutic Goods Administration (TGA), Australia’s medicines regulator, has sought more information from Pfizer after a respected medical journal alleged serious problems with its vaccine safety trials in the United States. The British Medical Journal’s report published on Nov. 2 is based on the allegations of a former employee of Texas-based Ventavia Research Group, a contractor involved in Pfizer’s phase III trial for COVID vaccine in 2020. The whistleblower, Brook Jackson, who worked at Ventavia as a regional director, provided The BMJ with “dozens of internal company documents, photos, audio recordings, and emails.” According to Jackson, Pfizer “falsified data, unblinded patients, employed inadequately trained vaccinators, and was slow to follow up on adverse events reported in Pfizer’s pivotal phase III trial.” After repeatedly notifying Ventavia of these problems, Jackson emailed a complaint to the US Food and Drug Administration (FDA) on Sept. 25, 2020. She was then fired by Ventavia later the same …